Abstract:The discovery of efficient and specific HIV-latency-reversing agents is critical for HIV therapy. Here, we developed wikstroelide E, a daphnane diterpene from the buds of Wikstroemia chamaedaphne, as a potential HIV-latency-reversing agent that is 2500-fold more potent than the drug prostratin. Based on transcriptome analysis, the underlying mechanism was that wikstroelide E regulated the MAPK, PI3K-Akt, JAK-Stat, TNF, and NF-κB signaling pathways. We clearly demonstrated that wikstroelide E reversed latent HIV infection by activating PKC-NF-κB signals, serving as a proxy for verifying the transcriptome data. Strikingly, the Tat protein contributes to the robust activation of latent HIV in wikstroelide-E-treated cells, producing an unexpected latency-reversing effect against latent HIV. This study provides the basis for the potential development of wikstroelide E as an effective HIV-latency-reversing agent.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jnatprod.0c01039?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jnatprod.0c01039</a>.Cytotoxicity evaluation, S2 GO analysis of DEPs, KEGG analysis of DEPs, 1H NMR spectra, and 13C NMR spectra (<a class="ext-link" href="/doi/suppl/10.1021/acs.jnatprod.0c01039/suppl_file/np0c01039_si_001.pdf">PDF</a>)Comparison of the gene expression levels among all groups (<a class="ext-link" href="/doi/suppl/10.1021/acs.jnatprod.0c01039/suppl_file/np0c01039_si_002.xlsx">XLSX</a>)Reliably quantified DEPs (<a class="ext-link" href="/doi/suppl/10.1021/acs.jnatprod.0c01039/suppl_file/np0c01039_si_003.xlsx">XLSX</a>)Molecular functions enriched in DEGs from cells subjected to wikstroelide E treatment for 6 h (<a class="ext-link" href="/doi/suppl/10.1021/acs.jnatprod.0c01039/suppl_file/np0c01039_si_004.xlsx">XLSX</a>)KEGG enrichment analysis performed to annotate the DEGs (<a class="ext-link" href="/doi/suppl/10.1021/acs.jnatprod.0c01039/suppl_file/np0c01039_si_005.xlsx">XLSX</a>)NF-κB target genes robustly upregulated after addition of wikstroelide E (<a class="ext-link" href="/doi/suppl/10.1021/acs.jnatprod.0c01039/suppl_file/np0c01039_si_006.xlsx">XLSX</a>)This article has not yet been cited by other publications.

Scopoletin Reactivates Latent HIV-1 by Inducing NF-κB Expression without Global T Cell Activation

Scopoletin Reactivates Latent HIV-1 by Inducing NF-?B Expression without Global T Cell Activation

Reactivation of HIV-1 from Latency by an Ingenol Derivative from Euphorbia Kansui

Reactivation of latent HIV-1 in latently infected cells by coumarin compounds: Hymecromone and ScoparoneReactivation of Latent HIV-1 in Latently Infected Cells by Coumarin Compounds: Hymecromone and Scoparone

Dual effects of the novel ingenol derivatives on the acute and latent HIV-1 infections

Dilazep Synergistically Reactivates Latent HIV-1 in Latently Infected Cells.

Quercetin Synergistically Reactivates Human Immunodeficiency Virus Type 1 Latency by Activating Nuclear Factor‑κb.

Pharmacological suppression of glycogen synthase kinase-3 reactivates HIV-1 from latency via activating Wnt/beta-catenin/TCF1 axis in CD4(+) T cells

Small-molecule Screening Using a Human Primary Cell Model of HIV Latency Identifies Compounds That Reverse Latency Without Cellular Activation.

NSC95397 is a Novel HIV-1 Latency Reversing Agent

A Chalcone Derivative Reactivates Latent HIV-1 Transcription Through Activating P-TEFb and Promoting Tat-SEC Interaction on Viral Promoter.

Discovering the Mechanisms of Oleodaphnone as a Potential HIV Latency-Reversing Agent by Transcriptome Profiling

Resveratrol Promotes HIV-1 Tat Accumulation via AKT/FOXO1 Signal-ing Axis and Potentiates Vorinostat to Antagonize HIV-1 Latency

Oxaliplatin Antagonizes HIV-1 Latency by Activating NF-κB Without Causing Global T Cell Activation.

Curaxin CBL0137 Has the Potential to Reverse HIV‐1 Latency

A Natural Product From Polygonum Cuspidatum Sieb. Et Zucc. Promotes Tat-Dependent Hiv Latency Reversal Through Triggering P-Tefb'S Release From 7sk Snrnp

Wogonin Inhibits Latent HIV-1 Reactivation by Downregulating Histone Crotonylation

Mechanisms and efficacy of small molecule latency-promoting agents to inhibit HIV reactivation ex vivo

A Novel Bromodomain Inhibitor Reverses HIV-1 Latency Through Specific Binding with BRD4 to Promote Tat and P-TEFb Association.

A Novel Selective Histone Deacetylase I Inhibitor CC-4a Activates Latent HIV-1 Through NF-κB Pathway.

Discovering the Mechanisms of Wikstroelide E as a Potential HIV-Latency-Reversing Agent by Transcriptome Profiling